{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:44:04Z","timestamp":1778928244890,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.rmed.2023.107237","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T01:10:55Z","timestamp":1680829855000},"page":"107237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function"],"prefix":"10.1016","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-7839","authenticated-orcid":false,"given":"Jason Brandon","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-1047","authenticated-orcid":false,"given":"Purav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-5175","authenticated-orcid":false,"given":"Mohammad H.","family":"Alshaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1867","authenticated-orcid":false,"given":"Jorge","family":"Lascano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.rmed.2023.107237_bib1","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2023.107237_bib2","series-title":"Patient Registry 2020 Annual Data Report","volume":"vol. 2020","author":"Foundation","year":"2021"},{"key":"10.1016\/j.rmed.2023.107237_bib3","doi-asserted-by":"crossref","first-page":"dkv201","DOI":"10.1093\/jac\/dkv201","article-title":"Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1","author":"Huttner","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.rmed.2023.107237_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.rmed.2023.107237_bib5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.rmed.2023.107237_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr. Pulmonol."},{"issue":"9","key":"10.1016\/j.rmed.2023.107237_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med. Nov 1"},{"issue":"129","key":"10.1016\/j.rmed.2023.107237_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1183\/09059180.00006512","article-title":"Treatment of pulmonary exacerbations in cystic fibrosis","volume":"22","author":"Bhatt","year":"2013","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.rmed.2023.107237_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1592\/phco.19.8.620.31525","article-title":"A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis","volume":"19","author":"Bosso","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.rmed.2023.107237_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jac\/40.1.125","article-title":"Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics","volume":"40","author":"Vinks","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.rmed.2023.107237_bib11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(05)70218-8","article-title":"Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials","volume":"5","author":"Kasiakou","year":"2005","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2023.107237_bib12","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2023.107237_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-020-00981-0","article-title":"Pharmacokinetic and pharmacodynamic optimization of antibiotic therapy in cystic fibrosis patients: current evidences, gaps in knowledge and future directions","volume":"60","author":"Magr\u00e9ault","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.rmed.2023.107237_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","article-title":"Meropenem, cefepime, and piperacillin protein binding in patient samples","volume":"42","author":"Al-Shaer","year":"2020","journal-title":"Ther. Drug. Monit."},{"issue":"4","key":"10.1016\/j.rmed.2023.107237_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"8","key":"10.1016\/j.rmed.2023.107237_bib16","doi-asserted-by":"crossref","DOI":"10.2165\/00003088-200645080-00001","article-title":"Antibacterial dosing in intensive care","volume":"45","author":"Roberts","year":"2006","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.rmed.2023.107237_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archpedi.1992.02160190029013","article-title":"Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis","volume":"146","author":"Arguedas","year":"1992","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.rmed.2023.107237_bib18","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01477-06","article-title":"Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers","volume":"51","author":"Bulitta","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ppul.1950030212","article-title":"Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis","volume":"3","author":"Reed","year":"1987","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2023.107237_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ppul.1950040403","article-title":"Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis","volume":"4","author":"McCarty","year":"1988","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/ppul.22669","article-title":"Optimization of anti \u2010 pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins","volume":"48","author":"Zobell","year":"2013","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2005.02.011","article-title":"Pharmacodynamics of tobramycin in patients with cystic fibrosis","volume":"52","author":"Mouton","year":"2005","journal-title":"Diagn Microbiol. Infect Dis."},{"key":"10.1016\/j.rmed.2023.107237_bib23","series-title":"Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients","author":"Hahn","year":"2018"},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000857","article-title":"Optimization of aztreonam in combination with ceftazidime\/avibactam in a cystic fibrosis patient with chronic Stenotrophomonas maltophilia pneumonia using therapeutic drug monitoring: a case study","volume":"43","author":"Cowart","year":"2021","journal-title":"Ther. Drug Monit."},{"issue":"12","key":"10.1016\/j.rmed.2023.107237_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/PL00008370","article-title":"Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children","volume":"159","author":"Rappaz","year":"2000","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.rmed.2023.107237_bib26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl053","article-title":"Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis","volume":"57","author":"Han","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.rmed.2023.107237_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros."},{"issue":"11","key":"10.1016\/j.rmed.2023.107237_bib28","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2006.05.015","article-title":"Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis\u2014caution with trough concentrations","volume":"6","author":"Coulthard","year":"2007","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.rmed.2023.107237_bib30","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1002\/ppul.25441","article-title":"Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis","volume":"56","author":"Ochs","year":"2021","journal-title":"Pediatr. Pulmonol."},{"issue":"6","key":"10.1016\/j.rmed.2023.107237_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s150100050042","article-title":"Leukocytopenia, thrombocytopenia and fever related to piperacillin\/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis","volume":"27","author":"Reichardt","year":"1999","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.rmed.2023.107237_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2023.107237_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611123001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:21:23Z","timestamp":1748773283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611123001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":33,"alternative-id":["S0954611123001257"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107237","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2023.107237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107237"}}